Bruker has signed a $108 million cash deal to acquire the short-lived PhenomeX and absorb its single-cell research tools into its life sciences product catalog.

布鲁克已经签署了1.08亿美元的现金交易，以收购短暂的PhenomeX，并将其单细胞研究工具纳入其生命科学产品目录。

PhenomeX was formed earlier this year after Berkeley Lights bought up IsoPlexis, a former Fierce Medtech Fierce 15 winner, and adopted a new moniker through an all-stock transaction valued at $57.8 million. The two research hardware companies set out to provide analyses into live biological function by classifying secreted proteins on a cell-by-cell basis..

今年早些时候，Berkeley Lights收购了前激烈的Medtech激烈15赢家IsoPlexis，并通过价值5780万美元的全股交易采用了新名字，PhenomeX成立。这两家研究硬件公司着手通过逐个细胞分类分泌的蛋白质来提供对活生物功能的分析。。

Now, PhenomeX, with its installed base of more than 400 instruments, will serve as Bruker’s entry point into single-cell research and boost its spatial biology programs.

现在，PhenomeX的安装基地超过400台仪器，将成为布鲁克进入单细胞研究的切入点，并推动其空间生物学计划。

Its offerings—including Berkeley Lights’ Beacon platform and IsoPlexis’ IsoLight and IsoSpark proteomic barcoding systems—will sit alongside Bruker’s various analytical and diagnostic solutions as it becomes a wholly owned subsidiary. Priced at $1 per share, the deal is expected to close before the end of this year..

其产品包括Berkeley Lights的Beacon平台和Isolexis的IsoLight和IsoSpark蛋白质组条形码系统，将与布鲁克公司的各种分析和诊断解决方案并排，成为合资子公司。价格为每股1美元，预计该交易将在今年年底前结束。。

The Beacon Optofluidic system is designed to assist researchers in biologics development by characterizing tens of thousands of single cells in parallel, while keeping the cells healthy enough for additional DNA or protein profiling. Meanwhile, the IsoLight and IsoSpark instruments automate multiplexed measurements of the proteins released between different cells..

信标光流体系统旨在通过并行表征数万个单细胞来帮助研究人员进行生物制剂开发，同时保持细胞足够健康，以进行额外的DNA或蛋白质分析。同时，IsoLight和IsoSpark仪器可自动对不同细胞之间释放的蛋白质进行多重测量。。

“The unique single-cell analysis platforms of PhenomeX are enabling researchers to more rapidly and precisely unlock new insights in functional cell biology research leading to important discoveries across the large and rapidly growing markets of antibody therapeutics, cell line development, cell therapy and gene therapy,” said Mark Munch, president of Bruker’s NANO Group, which also houses its X-ray analysis instruments and tools for electron microscopy..

布鲁克纳米集团总裁马克·蒙奇（Mark Munch）说：“PhenomeX独特的单细胞分析平台使研究人员能够更快速，更精确地开启功能细胞生物学研究的新见解，从而在抗体治疗，细胞系开发，细胞治疗和基因治疗等庞大而迅速增长的市场中取得重要发现。”，它还装有用于电子显微镜的X射线分析仪器和工具。。